Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q1 EPS of ($0.31), $0.22 better than the analyst estimate of ($0.53).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.